Moderna Raises Full-Year COVID Vaccine Sales Forecast to $21 Billion

Moderna Raises Full-Year COVID Vaccine Sales Forecast to $21 Billion
A vial and sryinge are seen in front of a displayed Moderna logo in this illustration taken on Jan. 11, 2021. (Dado Ruvic/Reuters)
Reuters
3/25/2022
Updated:
3/25/2022

Moderna Inc on Thursday raised its full-year forecast for sales of its COVID-19 vaccine to roughly $21 billion from $19 billion.

The company in February forecast sales of $19 billion from its signed contracts, and option for $3 billion in additional purchases.

Moderna on Thursday forecast additional purchases of roughly $500 million.